Bayer is joining the bandwagon of drugmakers getting in on clinical trial transparency, signing on to share some of its data with researchers but stopping well short of industry trailblazers.
Oft-merged CRO giant PRA has expanded its large-molecule capabilities in the U.S., setting up a bioanalysis shop right next to its clinics to make for faster trials.
Germany's Evotec splits its operation between contract research for big-name third parties and in-house work on its own pipeline, riding its uncommon take on the CRO business to an uptick in revenue last quarter.
Chinese CRO WuXi PharmaTech notched another strong sales quarter, boosting its revenue by 11.3% thanks to escalating demand for its manufacturing services.
Quintiles, the world's largest CRO, is further expanding its outside-the-clinic business, agreeing to buy healthcare analytics outfit Encore Health Resources to beef up its access to real-world patient data.
Irish CRO Icon has closed out its $143.5 million acquisition of Aptiv Solutions, a deal designed to amp up its technology and expand its presence in Japan.
WuXi PharmaTech, China's largest CRO, is upping its capacity in its two largest markets, wrapping up an expansion of a U.S. early-stage operation and breaking ground on an R&D campus outside of Shanghai.
Chinese CRO Tigermed is buying its way into the U.S., signing a deal to trade $50.3 million for a majority stake in Pennsylvania's Frontage Laboratories.
Contract drug developer AMRI turned in a stagnant revenue quarter, watching profits slip as it prepares to shake off its dependence on royalties and embrace a future in large-scale manufacturing.
Avillion, a contract researcher that teams up on late-stage drugs in exchange for a cut of profits, has added the complementarily focused Royalty Pharma to its investor syndicate, joining VCs Abingworth and Clarus Ventures.
Non-clinical contract researcher Huntingdon Life Sciences has acquired Harlan Laboratories, boosting its stake in animal models and creating a combined company with revenue it says will reach near half a billion dollars a year.
Chinese outsourcing giant WuXi PharmaTech passed an FDA audit at one of its local facilities and broke ground on a new plant in the U.S., executing on its two-pronged strategy to take a bigger share of the global drug development market.
Covance's shares fell as much as 10% after the CRO missed its internal sales goals in the first quarter and dialed down its revenue projection for the year.
Charles River Laboratories posted a slight increase in sales last quarter, crediting a rise in preclinical demand as it counts on some new acquisitions to brighten 2014.
Quintiles, the world's largest CRO, hit the $1 billion service revenue threshold for the second time last quarter, piling up new business wins with eyes on its biggest year ever.
CRO giant Parexel is back on the up and up after a brief stumble in the fall, swinging to another profit as new business flows in.
CRO Icon posted another double-digit revenue jump in its fiscal first quarter, and now the Irish outfit is upping its annual guidance, counting on M&A and an expanding market share to pad its profits.
Piggybacking off an earlier deal, Bristol-Myers Squibb has signed another manufacturing agreement with South Korean giant Samsung.
When Big Pharma execs talk up "synergies" to convince shareholders to buy into mergers, they mean, in part, consolidating contractors. And, with all the megadeals rumored and real surfacing over the past week, CROs could be in for a revenue haircut as the drug business realigns.
Global contractor Catalent swung to a profit last quarter thanks to a slight sales increase and some ongoing restructuring, staying the course as it plans to go public in an IPO worth $100 million or more.